Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - ezetimibe 10mg; simvastatin 10mg - tablet - 10/10mg - active: ezetimibe 10mg simvastatin 10mg excipient: butylated hydroxyanisole citric acid monohydrate croscarmellose sodium hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose propyl gallate - homozygous familial hypercholesterolaemia vytorin is indicated for the reduction of elevated total-c and ldl-c levels in adult and adolescent (10 to 17 years of age) patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - ezetimibe 10mg; simvastatin 20mg - tablet - 10/20mg - active: ezetimibe 10mg simvastatin 20mg excipient: butylated hydroxyanisole citric acid monohydrate croscarmellose sodium hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose propyl gallate - homozygous familial hypercholesterolaemia vytorin is indicated for the reduction of elevated total-c and ldl-c levels in adult and adolescent (10 to 17 years of age) patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - ezetimibe 10mg; simvastatin 40mg - tablet - 10/40mg - active: ezetimibe 10mg simvastatin 40mg excipient: butylated hydroxyanisole citric acid monohydrate croscarmellose sodium hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose propyl gallate - homozygous familial hypercholesterolaemia vytorin is indicated for the reduction of elevated total-c and ldl-c levels in adult and adolescent (10 to 17 years of age) patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - ezetimibe 10mg; simvastatin 80mg - tablet - 10/80mg - active: ezetimibe 10mg simvastatin 80mg excipient: butylated hydroxyanisole citric acid monohydrate croscarmellose sodium hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose propyl gallate - homozygous familial hypercholesterolaemia vytorin is indicated for the reduction of elevated total-c and ldl-c levels in adult and adolescent (10 to 17 years of age) patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).

Israel - anglès - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - aprepitant - capsules - aprepitant 80 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

Israel - anglès - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - aprepitant - capsules - aprepitant 125 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - elbasvir 50mg; grazoprevir 100mg - film coated tablet - 50mg/100mg - active: elbasvir 50mg grazoprevir 100mg excipient: carnauba wax colloidal silicon dioxide copovidone croscarmellose sodium d-alpha tocoferol hypromellose lactose monohydrate magnesium stearate mannitol microcrystalline cellulose opadry beige 39k170006 sodium chloride sodium laurilsulfate - zepatier is indicated for the treatment of chronic hepatitis c genotypes 1, 3, or 4 infection in adults.

Estats Units - anglès - NLM (National Library of Medicine)

merck sharp & dohme llc - suvorexant (unii: 081l192fo9) (suvorexant - unii:081l192fo9) - suvorexant 5 mg - belsomra® (suvorexant) is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. belsomra is contraindicated in patients with narcolepsy. risk summary available data from postmarketing reports with belsomra use in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. in animal reproduction studies, oral administration of suvorexant to pregnant rats and rabbits during the period of organogenesis decreased maternal body weight and/or weight gain at doses ≥ 30 and 28 times the maximum recommended human dose (mrhd) of 20 mg based on auc in the rat and rabbit, respectively. suvorexant caused decreased fetal weight at doses ≥ 86 times the mrhd based on auc in the rat and did not cause significant fetal toxicity at doses up to 28 times the mrhd based on auc in the rabbit. the no observed adverse effect levels (noaels) for fetal toxicity are 25 and 28 times the mrhd based

Malàisia - anglès - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

merck sharp & dohme (malaysia) sdn bhd - metformin hydrochloride; sitagliptin phosphate -

Malàisia - anglès - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

merck sharp & dohme (malaysia) sdn bhd - metformin hydrochloride; sitagliptin phosphate -